Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2011 Aug;25(4):853-69. doi: 10.1016/j.hoc.2011.05.003.

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Author information

1
Department of Medical Oncology, Guy's Hospital, London, UK.

Abstract

Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors sorafenib, sunitinib, and pazopanib, the monoclonal antibody bevacizumab, and the mTOR inhibitors temsirolimus and everolimus. With the exception of temsirolimus, phase 3 trials tested these agents in patients with clear-cell histology; therefore, their efficacy in non-CCRCC is unclear. To date, there is no established effective therapy for patients with advanced non-CCRCC. This article focuses on treatment options for metastatic non-CCRCC.

PMID:
21763971
PMCID:
PMC4167832
DOI:
10.1016/j.hoc.2011.05.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center